Venture&Growth Archives - Gilde Healthcare

latest news

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement Multiple surgeons from multiple U.S. centers treat patients with knee osteoarthritis
September 6, 2023

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

test Withings introduces the hybrid watch that watches your health day and night with new capabilities to monitor body temperature 24/7, heart rate variability, respiratory rate and female menstrual cycles

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

test Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in 2016, Limbix has raised $30 million and has built a research-based pipeline of adolescent products. As a result of the […]

Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation

Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients who failed previous ablation International, multi-center trial at 21 sites with results expected in 2025 Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating...

Tagworks Pharmaceuticals announces $64 Million in Series A financing co-led by Gilde Healthcare

Tagworks Pharmaceuticals BV (“Tagworks”), the Dutch pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $64 million Series A financing led by Gilde Healthcare and Ysios Capital and with participation from international investors Novartis Venture Fund, New Enterprise Associates (NEA),...

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company. “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma. Ilise has the...

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council In three years’ time, Gilde Healthcare raised over...

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA  More than 32 million...

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series A extension financing, raising a further EUR 31M, following the EUR 51M...
These were all messages